4,552 publications from this institution
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
A total of 21 clones of acyclovir (ACV)-resistant (ACV(r)) herpes simplex virus type 1 (HSV-1) and 23 clones of penciclovir (PCV)-resistant (PCV(r)) HSV-1, emerging during serial passages in the presence of ACV or PCV, were isolated under conditions excluding contamination of resistant mutants in the starting virus culture, and their mutations in the thymidine kinase (TK) and DNA polymerase (DNA Pol) genes were analyzed comparatively. Mutations in the TK genes from ACV(r) mutants consisted of 50% single nucleotide substitutions and 50% frameshift mutations, while the corresponding figures for the PCV(r) mutants were 4 and 96%, respectively (P < 0.001). Eight of the 21 ACV(r) clones, but none of the 23 PCV(r) clones, had mutations in DNA Pol. Only nucleotide substitution(s) could be detected in the DNA Pol gene, as the gene is essential for virus replication. Therefore, the results for the DNA Pol mutants are concordant with those for the TK mutants in that a single nucleotide substitution was commonly observed in the ACV(r), but not in the PCV(r), mutants. These results clearly point to differential mutation patterns between ACV(r) and PCV(r) HSV-1 clones.
The discovery of interferon (IFN), as an antiviral substance, by Isaacs and Lindenmann in 1957 De Somer's original attempts were aimed at determining the mode of action of IFN [2], whereas Merigan's work focused on trying to understand the role of IFN in human viral diseases
Now more than 50 years after interferon was discovered, in 1957, by Isaacs and Lindenmann, this quinquagenarian has evidently come to age. Its major indications for clinical use are, for interferon-alpha, now mostly used in its pegylated form, the treatment of chronic hepatitis B and chronic hepatitis C, the latter generally in combination with ribavirin; and for interferon-beta, the treatment of multiple sclerosis (MS). Of quintessence in the 50 years with interferon has been the cloning of interferon-alpha and -beta in 1980, which not only proved its identity, but also laid the basis for its application in the treatment of hepatitis (B and C) and multiple sclerosis, respectively.
Regularly reviewing the state-of-the-art developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.